

February 16, 2009

AnGes MG, Inc.

Announcement about the progress of Allovectin-7® Phase 3 pivotal trial

AnGes MG, Inc.(AnGes) today announced the progress of Allovectin-7® Phase 3 trial for metastatic melanoma, based on the press release by Vical Inc.(Vical) on Feb.11<sup>th</sup>.

Vical is conducting the AIMM (Allovectin-7® Immunotherapeutic for Metastatic Melanoma) Phase 3 pivotal trial targeting enrollment of approximately 375 patients with Stage III or IV metastatic melanoma. The trial is expected to complete enrollment of the planned 375 subjects within 2009.

“We are making great progress recruiting patients as we continue to expand beyond North America to clinical sites across Western and Eastern Europe, into Israel, and recently into Turkey with the help of our commercialization partner Eczacibasi,” said Vijay B. Samant, Vical’s President and Chief Executive Officer. “Including our sites in the United States and Canada, we expect to have more than 100 active clinical sites in key centers worldwide as we advance toward our final months of enrollment. Based on the trends across these regions, we are confident that we will complete enrollment in this pivotal Phase 3 trial by the end of the year.”

As announced on May 30<sup>th</sup>, '06, AnGes and Vical executed a R&D and an investment agreement, related to the pivotal Phase 3 trial of Allovectin-7®. Based on these agreements, AnGes is obligated to pay Vical a total of \$22.6 million (consisting of cash and equity investments) for the conduct of trial costs. AnGes has paid a total of \$17.6 million as of Feb '09. The remaining amount will be paid by the end of this year based on the progress of this trial. (The profit forecast disclosed on Feb. 6<sup>th</sup> includes the impact from these payments.)

In exchange of funding the trial, AnGes received the rights to receive certain royalties for sales of Allovectin-7® in the United States and Europe, as well as exclusive marketing rights in Japan and other key Asian countries. AnGes expects that together with the future income through its lead product, HGF / Collategene, the income from the royalties of Allovectin-7® would largely contribute to improve its performance and establish its base of profitability. AnGes is encouraged by the progress of this trial and is looking forward to further advancements.

<Company Information>

Company name : Vical Inc.  
Head office : 10390 Pacific Center Court, San Diego, CA 92121, USA  
President and CEO : Vijay B. Samant  
Foundation : 1987  
Employee number : 118 (as of December 2008)  
Business : Research and development of biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases including infectious diseases and cancer.